Variation in the care of surgical conditions: Prostate cancer

Despite many years of attention and study, variation in the diagnosis and treatment of prostate cancer persists in the United States. While some progress has been made--for example, screening practices are becoming more risk-based than population-based--new questions have arisen: for example, how be...

Full description

Bibliographic Details
Main Authors: Hyams, Elias S., Goodney, Philip P. (Author), Dzebisashvili, Nino (Author), Goodman, David C. (Author)
Corporate Authors: Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Atlas Project
Format: eBook
Language:English
Published: [Lebanon, N.H.] The Dartmouth Institute for Health Policy and Clinical Practice 2014, [2014]
Series:Dartmouth atlas of health care series
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01920nam a2200289 u 4500
001 EB002153011
003 EBX01000000000000001291137
005 00000000000000.0
007 tu|||||||||||||||||||||
008 230403 r ||| eng
100 1 |a Hyams, Elias S. 
245 0 0 |a Variation in the care of surgical conditions: Prostate cancer  |h Elektronische Ressource  |c Elias S. Hyams, Philip R. Goodney, Nino Dzebisashvili, David C. Goodman, Kristen K. Bronner 
246 3 1 |a Prostate cancer 
260 |a [Lebanon, N.H.]  |b The Dartmouth Institute for Health Policy and Clinical Practice  |c 2014, [2014] 
300 |a 1 PDF file (iii, 42 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
700 1 |a Goodney, Philip P.  |e [author] 
700 1 |a Dzebisashvili, Nino  |e [author] 
700 1 |a Goodman, David C.  |e [author] 
710 2 |a Dartmouth Institute for Health Policy and Clinical Practice 
710 2 |a Dartmouth Atlas Project 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Dartmouth atlas of health care series 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK586763  |3 Volltext 
082 0 |a 610 
520 |a Despite many years of attention and study, variation in the diagnosis and treatment of prostate cancer persists in the United States. While some progress has been made--for example, screening practices are becoming more risk-based than population-based--new questions have arisen: for example, how best to counsel patients regarding their risk of cancer and the benefits and trade-offs of treatment; how to optimize outcomes related to treatment; and which patients are best treated with active surveillance. While these questions are being answered, clinicians and health systems need to strive to incorporate the best available evidence and shared decision-making into their efforts to detect and treat prostate cancer